ONMD OneMedNet Corp
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1849380 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY365.1%
TTM net income YoY-412.3%
TTM EPS YoY-14,000.0%
Revenue 3-yr CAGR33.7%
Net income 3-yr CAGR—
Margins
Gross margin-49.7%
Operating margin-440.0%
Net margin-452.9%
FCF margin-285.4%
EBITDA margin-438.6%
Returns
ROE—
ROA-506.7%
ROIC (approx.)—
Asset turnover1.12x
Leverage & solvency
Liabilities / assets277.5%
Debt / equity—
Current ratio0.38x
Interest coverage-289.40x
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-188.2%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.36M | $643,000 | $1.02M | $1.15M | — |
| Cost of revenue | $1.86M | $924,000 | $1.15M | $1.51M | — |
| Gross profit | -$503,000 | -$281,000 | -$129,000 | -$360,000 | — |
| R&D expense | $1.51M | $1.47M | $2.06M | $1.59M | — |
| SG&A expense | $6.38M | $7.03M | $3.54M | $4.81M | — |
| Operating income | -$9.67M | -$9.61M | -$6.85M | -$7.71M | — |
| Interest expense | $67,000 | $147,000 | $11,000 | $403,307 | — |
| Pretax income | -$2.80M | -$10.13M | -$33.76M | -$30.43M | — |
| Income tax | $1,000 | $2,000 | $18,000 | $17,000 | — |
| Net income | -$2.80M | -$10.13M | -$33.78M | -$30.45M | — |
| EBITDA | -$9.60M | -$9.55M | -$6.83M | -$7.69M | — |
| EPS (basic) | -0.06 | -0.36 | -4.65 | -7.66 | — |
| EPS (diluted) | -0.06 | -0.36 | -4.65 | -7.66 | — |
| Weighted avg. shares (diluted) | 44.55M | 28.08M | 7.27M | 3.97M | — |
| Balance sheet | |||||
| Cash & equivalents | $585,000 | $172,000 | $47,000 | $271,000 | $453,151 |
| Receivables | $495,000 | $213,000 | $152,000 | $19,000 | — |
| Current assets | $2.10M | $3.62M | $365,000 | $391,000 | $536,212 |
| PP&E, net | $56,000 | $108,000 | $99,000 | $83,000 | — |
| Total assets | $2.15M | $3.73M | $464,000 | $1.29M | $117.86M |
| Current liabilities | $4.83M | $19.23M | $13.84M | $26.10M | $289,980 |
| Short-term debt | $974,000 | $9.38M | $465,000 | — | — |
| Long-term debt | $220,000 | $2.32M | $465,000 | — | — |
| Total debt | $1.19M | $11.70M | $930,000 | — | — |
| Total liabilities | $5.12M | $19.68M | $13.91M | $27.65M | $9.17M |
| Shareholders' equity | -$2.96M | -$15.95M | -$13.44M | -$26.36M | -$7.05M |
| Net debt | $609,000 | $11.53M | $883,000 | — | — |
| Shares outstanding | 5.18M | 27.99M | 23.57M | 4.03M | — |
| Cash flow statement | |||||
| Operating cash flow | -$7.50M | -$6.95M | -$4.79M | -$4.70M | — |
| Capital expenditure | $13,000 | $51,000 | $44,000 | $58,000 | — |
| Free cash flow | -$7.52M | -$7.00M | -$4.83M | -$4.76M | — |
| Investing cash flow | $2.31M | -$1.98M | -$44,000 | -$58,000 | — |
| Financing cash flow | $5.61M | $9.06M | $4.61M | $4.33M | — |
| Depreciation & amortization | $65,000 | $57,000 | $28,000 | $25,000 | — |
| Stock-based compensation | $2.03M | $628,000 | $1.48M | $1.86M | $47,071 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.